{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:34:43Z","timestamp":1786649683765,"version":"build-2736575974"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Head and neck cancer (HNC) is a major global health concern. Despite advances in treatment, the outcome is poor due to locoregional failure. Enhancer of zeste homolog 2 (EZH2), an epigenetic modifier, plays a role in cancer development by promoting growth, invasion, and dissemination of tumor cells. This study aims to investigate the correlation between EZH2 expression and the response to chemoradiation (CRT) in patients with locally advanced, inoperable oral cavity and oropharyngeal squamous cell cancers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Fifty patients were prospectively included in this study. All of the patients received definitive CRT. A second biopsy was retrieved between the third and fourth fractions of radiotherapy (RT). Immunohistochemistry (IHC) was performed on pre-RT and postthird fraction biopsy samples to evaluate EZH2 status. The IHC score was calculated based on EZH2 intensity and the percentage of positive cells. A score of 4 or more indicated high expression. After 12 weeks of treatment completion, the response was assessed and correlated with EZH2 status, and the statistical analysis was done.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>The EZH2 score was significantly higher in tumor tissue than in normal tissue samples (P value: 0.001). High expression of EZH2 was found in 78% of pre-RT and 81% of postthird fraction tumor samples. High expression of EZH2 did not show a statistically significant correlation with response to CRT (P value: 0.809). However, the EZH2 score increased significantly in the postthird fraction samples of patients who did not achieve a complete response (P value: 0.03).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>The study indicates that EZH2 can be a valuable predictive marker in HNC. Anti-EZH2 therapy should be explored to improve the treatment outcomes in patients with high expression of EZH2.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/jcrt.jcrt_1467_25","type":"journal-article","created":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T17:01:00Z","timestamp":1767200460000},"page":"1391-1397","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Correlation of EZH2 expression and response to chemoradiation in patients with locally advanced inoperable oral cavity and oropharyngeal squamous cell cancers"],"prefix":"10.4103","volume":"21","author":[{"given":"S. K. Soel","family":"Ahmed","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, All India Institute of Medical Sciences, Bhubaneswar, Odisha, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saroj Kumar Das","family":"Majumdar","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, All India Institute of Medical Sciences, Bhubaneswar, Odisha, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit Kumar","family":"Adhya","sequence":"additional","affiliation":[{"name":"Department of Pathology and Lab Medicine, All India Institute of Medical Sciences, Bhubaneswar, Odisha, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandip Kumar","family":"Barik","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, All India Institute of Medical Sciences, Bhubaneswar, Odisha, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak Kumar","family":"Das","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, All India Institute of Medical Sciences, Bhubaneswar, Odisha, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathan Kumar","family":"Ramasubbu","sequence":"additional","affiliation":[{"name":"Nference Labs Private Limited, Bengaluru, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyanka","family":"Mukherjee","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anupam","family":"Muraleedharan","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Amrita Institute of Medical Sciences, Kochi, Kerala, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nehla","family":"Haroon","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, All India Institute of Medical Sciences, Bhubaneswar, Odisha, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ankur","family":"Mahajan","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, All India Institute of Medical Sciences, Bhubaneswar, Odisha, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaha Sheik","family":"Abdulla","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, All India Institute of Medical Sciences, Bhubaneswar, Odisha, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnab","family":"Sarkar","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, All India Institute of Medical Sciences, Bhubaneswar, Odisha, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phanindra Kumar","family":"Swain","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, All India Institute of Medical Sciences, Bhubaneswar, Odisha, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pradipta Kumar","family":"Parida","sequence":"additional","affiliation":[{"name":"Department of ENT, All India Institute of Medical Sciences, Bhubaneswar, Odisha, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dillip Kumar","family":"Muduly","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, All India Institute of Medical Sciences, Bhubaneswar, Odisha, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dillip Kumar","family":"Parida","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, All India Institute of Medical Sciences, Bhubaneswar, Odisha, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,12,31]]},"reference":[{"key":"R1-20260102","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1038\/s41415-022-5166-x","article-title":"Reviewing the epidemiology of head and neck cancer:Definitions, trends and risk factors","volume":"233","author":"Gormley","year":"2022","journal-title":"Br Dent J"},{"key":"R2-20260102","first-page":"80","article-title":"Multiple cancers of the head and neck","volume":"8","author":"Heroiu","year":"2013","journal-title":"Maedica (Bucur)"},{"key":"R3-20260102","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1186\/s12885-020-07297-z","article-title":"Treatment strategy and outcomes in locally advanced head and neck squamous cell carcinoma:A nationwide retrospective cohort study (KCSG HN13-01)","volume":"20","author":"Lee","year":"2020","journal-title":"BMC Cancer"},{"key":"R4-20260102","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1038\/sj.bjc.6602510","article-title":"State-of-the-art management of locally advanced head and neck cancer","volume":"92","author":"Seiwert","year":"2005","journal-title":"Br J Cancer"},{"key":"R6-20260102","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.oraloncology.2015.11.002","article-title":"EZH2 is associated with poor prognosis in head-and-neck squamous cell carcinoma via regulating the epithelial-to-mesenchymal transition and chemosensitivity","volume":"52","author":"Chang","year":"2016","journal-title":"Oral Oncol"},{"key":"R7-20260102","first-page":"e36946","article-title":"Evaluation of immunohistochemical expression of enhancer of Zeste Homolog 2 (EZH2) and its association with clinicopathological variables in carcinoma cervix","volume":"15","author":"Priya","year":"2023","journal-title":"Cureus"},{"key":"R8-20260102","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s40463-016-0168-9","article-title":"Investigation of EZH2 pathways for novel epigenetic treatment strategies in oropharyngeal cancer","volume":"45","author":"Idris","year":"2016","journal-title":"J Otolaryngol Head Neck Surg"},{"key":"R9-20260102","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.oraloncology.2008.03.016","article-title":"High expression of EZH2 is associated with tumor proliferation and prognosis in human oral squamous cell carcinomas","volume":"45","author":"Kidani","year":"2009","journal-title":"Oral Oncol"},{"key":"R10-20260102","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1038\/169965a0","article-title":"Effect of ionizing radiation on protein denaturation","volume":"169","author":"Fricke","year":"1952","journal-title":"Nature"},{"key":"R11-20260102","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/mc.21848","article-title":"Polycomb group protein EZH2-mediated E-cadherin repression promotes metastasis of oral tongue squamous cell carcinoma","volume":"52","author":"Wang","year":"2013","journal-title":"Mol Carcinog"},{"key":"R12-20260102","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/jop.12673","article-title":"EZH2 overexpression in head and neck cancer is related to lymph node metastasis","volume":"47","author":"Nienstedt","year":"2018","journal-title":"J Oral Pathol Med"},{"key":"R13-20260102","doi-asserted-by":"crossref","first-page":"33720","DOI":"10.18632\/oncotarget.5606","article-title":"Targeting EZH2 regulates tumor growth and apoptosis through modulating mitochondria dependent cell-death pathway in HNSCC","volume":"6","author":"Zhou","year":"2015","journal-title":"Oncotarget"},{"key":"R14-20260102","doi-asserted-by":"crossref","first-page":"263","DOI":"10.4132\/KoreanJPathol.2014.48.4.263","article-title":"The clinicopathological significance of epithelial mesenchymal transition associated protein expression in head and neck squamous cell carcinoma","volume":"48","author":"Kim","year":"2014","journal-title":"Korean J Pathol"},{"key":"R15-20260102","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1158\/1940-6207.CAPR-11-0130","article-title":"EZH2 promotes malignant phenotypes and is a predictor of oral cancer development in patients with oral leukoplakia","volume":"4","author":"Cao","year":"2011","journal-title":"Cancer Prev Res (Phila)"},{"key":"R16-20260102","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.18632\/oncotarget.1503","article-title":"The polycomb group protein EZH2 is a novel therapeutic target in tongue cancer","volume":"4","author":"Li","year":"2013","journal-title":"Oncotarget"},{"key":"R17-20260102","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.cell.2006.02.043","article-title":"Control of developmental regulators by Polycomb in human embryonic stem cells","volume":"125","author":"Lee","year":"2006","journal-title":"Cell"},{"key":"R18-20260102","doi-asserted-by":"crossref","first-page":"5323","DOI":"10.1093\/emboj\/cdg542","article-title":"EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer","volume":"22","author":"Bracken","year":"2003","journal-title":"EMBO J"},{"key":"R19-20260102","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1038\/sj.onc.1208462","article-title":"Regulation of epidermal apoptosis and DNA repair by E2F1 in response to ultraviolet B radiation","volume":"24","author":"Berton","year":"2005","journal-title":"Oncogene"},{"key":"R20-20260102","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1002\/ijc.23145","article-title":"EZH2, Ki-67 and MCM7 are prognostic markers in prostatectomy treated patients","volume":"122","author":"Laitinen","year":"2008","journal-title":"Int J Cancer"},{"key":"R21-20260102","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s13046-014-0058-9","article-title":"EZH2 expression correlates with locoregional recurrence after radiation in inflammatory breast cancer","volume":"33","author":"Debeb","year":"2014","journal-title":"J Exp Clin Cancer Res"},{"key":"R22-20260102","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1186\/1748-717X-9-188","article-title":"The prognostic role of EZH2 expression in rectal cancer patients treated with neoadjuvant chemoradiotherapy","volume":"9","author":"Meng","year":"2014","journal-title":"Radiat Oncol"},{"key":"R23-20260102","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1002\/ijc.25031","article-title":"High expression of EZH2 is associated with tumor aggressiveness and poor prognosis in patients with esophageal squamous cell carcinoma treated with definitive chemoradiotherapy","volume":"127","author":"He","year":"2010","journal-title":"Int J Cancer"},{"key":"R24-20260102","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.wjorl.2019.06.001","article-title":"Update on oral and oropharyngeal cancer staging - International perspectives","volume":"6","author":"Kato","year":"2020","journal-title":"World J Otorhinolaryngol Head Neck Surg"},{"key":"R25-20260102","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1093\/annonc\/mdy060","article-title":"Evaluation of the eighth TNM classification on p16-positive oropharyngeal squamous cell carcinomas in the Netherlands and the importance of additional HPV DNA testing","volume":"29","author":"Nauta","year":"2018","journal-title":"Ann Oncol"}],"container-title":["Journal of Cancer Research and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_1467_25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T18:57:02Z","timestamp":1786647422000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_1467_25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":24,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.4103\/jcrt.jcrt_1467_25","relation":{},"ISSN":["0973-1482","1998-4138"],"issn-type":[{"value":"0973-1482","type":"print"},{"value":"1998-4138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"2025-07-15","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-22","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}